Latest news with #TempusAI
Yahoo
15 hours ago
- Business
- Yahoo
Why Tempus AI, Inc. (TEM) Skyrocketed On Monday
We recently published a list of . In this article, we are going to take a look at where Tempus AI, Inc. (NASDAQ:TEM) stands against other top-performing stocks on Monday. Tempus AI extended its winning streak to a third consecutive day on Monday, jumping 15.02 percent to close at $63.47 apiece as investors snapped up shares after earning a 'buy' recommendation despite being hit by a negative short-seller report. On Monday, TD Cowen maintained its 'buy' recommendation on Tempus AI, Inc.'s (NASDAQ:TEM), pricing it at $62, albeit lower than its latest closing price. The recommendation followed Spruce Point Capital's report on the company, saying it sees a '50 to 60 percent potential long-term downside and market underperformance risk.' Photo by CDC on Unsplash 'We believe the Tempus equity growth story is built on hype and appeal to retail investors that it is an exciting and disruptive technology play with AI appeal, which could have the next Tesla or Nvidia-type inflection,' Spruce Point was quoted as saying. For its part, Tempus AI, Inc. (NASDAQ:TEM) said that it would not respond to a report 'riddled with hypotheticals and inaccuracies.' 'We remain focused on delivering shareholder value, taking advantage of the enormous opportunity of bringing AI to healthcare, and helping patients live longer and healthier lives,' it said. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
18 hours ago
- Business
- Yahoo
Why Tempus AI, Inc. (TEM) Skyrocketed On Monday
We recently published a list of . In this article, we are going to take a look at where Tempus AI, Inc. (NASDAQ:TEM) stands against other top-performing stocks on Monday. Tempus AI extended its winning streak to a third consecutive day on Monday, jumping 15.02 percent to close at $63.47 apiece as investors snapped up shares after earning a 'buy' recommendation despite being hit by a negative short-seller report. On Monday, TD Cowen maintained its 'buy' recommendation on Tempus AI, Inc.'s (NASDAQ:TEM), pricing it at $62, albeit lower than its latest closing price. The recommendation followed Spruce Point Capital's report on the company, saying it sees a '50 to 60 percent potential long-term downside and market underperformance risk.' Photo by CDC on Unsplash 'We believe the Tempus equity growth story is built on hype and appeal to retail investors that it is an exciting and disruptive technology play with AI appeal, which could have the next Tesla or Nvidia-type inflection,' Spruce Point was quoted as saying. For its part, Tempus AI, Inc. (NASDAQ:TEM) said that it would not respond to a report 'riddled with hypotheticals and inaccuracies.' 'We remain focused on delivering shareholder value, taking advantage of the enormous opportunity of bringing AI to healthcare, and helping patients live longer and healthier lives,' it said. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
a day ago
- Business
- Yahoo
Tempus AI rebound, Meta's AI ad push, Broadcom earnings optimism
Market Domination co-host Julie Hyman tracks today's top moving stocks and biggest market stories in this Market Minute. Tempus AI (TEM) shares jump after TD Cowen responded to a recent short report, calling some of its claims exaggerated. Advertising stocks fall as Meta (META) reportedly plans to fully automate ad creation and targeting with artificial intelligence (AI) by the end of next year, according to The Wall Street Journal. Meanwhile, Broadcom (AVGO) shares rise ahead of its June 5 earnings report. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute. Sign in to access your portfolio
Globe and Mail
a day ago
- Business
- Globe and Mail
Tempus AI Stock (TEM) Could See ‘Tesla or Nvidia-Type Inflection,' Claims Short Seller
AI (TEM) came under intense pressure after a scathing short seller report raised red flags about the company's valuation, business model, and financial transparency. The bearish hedge fund Spruce Point Capital report compared TEM stock's potential trajectory to tech names like Tesla (TSLA) and Nvidia (NVDA), warning investors of a looming 'inflection point.' Confident Investing Starts Here: Tempus AI specializes in data-driven solutions for the healthcare industry with a focus on oncology and genomics. TEM Stock Rattled by Explosive Short Seller Claims The Spruce report warns of a potential 50% to 60% long-term downside for TEM stock and a high risk of market underperformance. The firm argued that Tempus' growth story is largely driven by hype and retail investor enthusiasm, fueled by the company's positioning as an exciting AI-driven tech disruptor. However, Spruce Point cautioned investors to look past the buzz, pointing instead to concerns over aggressive accounting practices, financial engineering, related-party transactions, and overall earnings quality. The report also criticized the company's billing practices, highlighting an aggressive use of billing code 81479, known for minimal oversight and a higher risk of misuse. According to the report, this approach could artificially boost revenue, potentially prioritizing financial gains over patient care. Additionally, the report raised concerns about Tempus AI's leadership, pointing to CEO Eric Lefkofsky's past involvement with companies that faced financial scandals, including bankruptcies and restatements. Following these claims, TEM stock crashed over 19% on Wednesday. Still, despite the sharp drop, the stock remains up 58% year-to-date. Tempus Rejects Short-Seller Claims Tempus AI dismissed the short-seller allegations, calling the report 'riddled with hypotheticals and inaccuracies' and failing to reflect the company's solid track record of financial performance and growth. Is Tempus a Good Stock to Buy? There's no denying the risks with Tempus AI. But Spruce Point's report doesn't introduce any new red flags; it simply amplifies existing concerns. On TipRanks, TEM stock has received a Moderate Buy rating based on six Buy and three Hold recommendations. The Tempus AI share price forecast is $66.25, which implies an upside of 25% from the current level. See more TEM analyst ratings
Business Wire
a day ago
- Business
- Business Wire
Tempus Introduces xM, An Assay to Monitor Immunotherapy Response for Patients with Advanced Cancers
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced xM for treatment response monitoring (TRM), a liquid biopsy assay intended to detect molecular response to immune-checkpoint inhibitor (ICI) therapy in advanced solid tumors. xM for TRM is the newest addition to Tempus' growing portfolio of sensitive assays for monitoring molecular response and minimal residual disease (MRD). It is currently available for research use only, with clinical availability expected later this year. In 2023, an estimated 56.55% of patients with advanced or metastatic cancers were eligible for ICIs, with a corresponding estimated response rate of 20.13%. 1 xM for TRM is designed to quantify changes in circulating tumor DNA (ctDNA) longitudinally from a blood sample, enabling early molecular response assessment in patients with advanced cancers receiving immunocheckpoint inhibitors (ICI) alone or combination therapies. xM for TRM leverages a unique multi-parametric algorithm, integrating copy number variations (CNVs), along with somatic and germline variant allele frequencies (VAFs), for a comprehensive and robust estimation of circulating tumor fraction. Tempus is presenting new data on xM for TRM at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting, highlighting the assay's potential to help clinicians monitor response and refine treatment strategies for patients with advanced cancers. Title: A molecular biomarker for longitudinal monitoring of therapeutic efficacy in a real-world cohort of advanced solid tumors treated with immune checkpoint inhibitors Date/Time: Location: Poster Section Developmental Therapeutics—Immunotherapy (Poster #205) Overview: Tempus xM for TRM, a liquid biopsy test, monitors treatment response by tracking ctDNA dynamics over time. Longitudinal non-molecular responders are associated with worse survival compared to molecular responders, highlighting the value of xM molecular response monitoring as a tool to guide ICI treatment decisions. 'Our comprehensive monitoring portfolio is designed to support patients throughout the cancer treatment journey,' said Halla Nimeiri, MD, Chief Development Officer at Tempus. 'We're excited to introduce a new assay of molecular response for both physicians and biopharma researchers that can timely track changes of quantitative tumor fraction while patients receive ICI therapies. This may impact treatment decisions, especially for patients with advanced disease, where timing is absolutely critical. With xM for TRM, clinicians can detect molecular response to ICI prior to six weeks into treatment, enabling them to stay ahead of disease progression and optimize therapeutic strategies.' About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the potential impact of xM TRM and other tests, the indicated use of the xM TRM and other tests for potential clinical use, and the timing of the availability of such testing, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'going to,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release. You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled 'Risk Factors' in Tempus' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on February 24, 2025, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
